Metformin, a drug commonly used to treat diabetes, may prevent the development of “long COVID,” according to a clinical trial published in The Lancet Infectious Diseases.
Menu
Browsing: COVID-19
A novel protein developed by Northwestern Medicine investigators improved survival and prevented brain infection in mice infected with SARS-CoV-2 when administered intranasally, according to a recent study.
Secondary bacterial pneumonia that did not resolve was a key driver of death in patients with COVID-19, according to a recent study in the Journal of Clinical Investigation.
A new Northwestern Medicine study shows antibodies generated by prior vaccinations or infections can actually “hurt” subsequent COVID-19 booster shots.
Northwestern Medicine investigators continue to study the impact of the COVID-19 pandemic on health outcomes and society, from maternal vaccinations and antibody response to reducing burnout amongst healthcare workers and identifying novel therapeutic targets.
Targeting internal proteins instead of spike proteins may be a promising strategy for monoclonal antibody therapy to combat SARS-CoV-2, the virus that causes COVID-19.
Northwestern Medicine investigators continue to investigate the impact of the COVID-19 pandemic, from evaluating repurposed drugs in preventing severe disease to using sentinel surveillance to monitor SARS-CoV-2 transmission rates and studying the prevalence of “long COVID” in pediatric patients.
Northwestern Medicine investigators continue to study COVID-19, from comparing mortality rates between SARS-CoV-2 variants to examining the effectiveness of maternal vaccination in protecting infants and combating COVID-19 misinformation on social media.
Tobias Holden, a fourth-year student in the Medical Scientist Training Program (MSTP), was lead author of a paper that used mathematical modeling to determine the impact of structural racism and health disparities on COVID-19 mortality rates in Illinois.
Metformin, a common, safe and inexpensive drug for type 2 diabetes, lowered the odds of emergency department visits, hospitalizations or death due to COVID-19 by over 40 percent, according to a new multi-site clinical trial.